Researchers at MD Anderson Cancer Center have defined a new oncogene for B-cell lymphomas. The cancer-causing gene, known as heterogeneous ribonucleoprotein K (hnRNPK), appears to lead to cancer development when overexpressed and may lead to new methods for assessing patients and to the development of new lymphoma treatment approaches.
Findings from the study, led by Sean Post, Ph.D., associate professor of Leukemia at MD Anderson...
MD Anderson’s Moon Shots Program has expanded its targets, adding some of the most intractable cancers to its campaign to more rapidly convert...